616224-19-2

Basic information

• Product Name: Benzyl 3,4-diaMinobenzoxylate
• Synonyms: Benzyl 3,4-diaMinobenzoxylate;3,4-DiaMinobenzoic acid benzyl ester;3,4-Diaminobenzoic acid phenylmethyl ester;Benzyl 3,4-diaminobenzoate
• CAS NO: 616224-19-2
• Molecular Formula: C₁₄H₁₄N₂O₂
• Molecular Weight: 322.40088
• Mol File: 616224-19-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 478.7±30.0 °C(Predicted)
• Appearance: /
• Density: 1.257±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C
• PKA: 2.97±0.10(Predicted)
• CAS DataBase Reference: Benzyl 3,4-diaMinobenzoxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl 3,4-diaMinobenzoxylate(616224-19-2)
• EPA Substance Registry System: Benzyl 3,4-diaMinobenzoxylate(616224-19-2)

Safety Data

• Hazardous Substances Data: 616224-19-2(Hazardous Substances Data)

Usage

General Description

Benzyl 3,4-diaMinobenzoxylate is a chemical compound with the molecular formula C21H24N2O3. It is a benzilyl derivative of 3,4-diaMinobenzoxylate, which is a synthetic compound used in pharmaceutical research and drug development. Benzyl 3,4-diaMinobenzoxylate is commonly used as a building block in the synthesis of various pharmaceutical compounds and may also have potential biological activity. Its chemical structure contains a benzyl group attached to a 3,4-diaMinobenzoxylate moiety, contributing to its properties and reactivity. Benzyl 3,4-diaMinobenzoxylate is important in the field of medicinal chemistry and drug discovery, and its unique structure and properties make it a valuable tool for researchers in the pharmaceutical industry.

Upstream product

• 1004647-09-9 benzyl 4-amino-3-nitrobenzoate 

Downstream Products

• 1227962-26-6 C₂₀H₂₁N₃O₄ 

Relevant articles and documents

NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES

This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.